Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial

被引：0
|
作者：
Cork, Michael J. [1 ]
Beck, Lisa A. [2 ]
Deleuran, Mette [3 ]
Hong, H. Chih-ho [4 ,5 ]
Adam, David N. [5 ,6 ,7 ]
Hussain, Iftikhar [8 ]
Zhang, Haixin [9 ]
Shabbir, Arsalan [9 ]
Rodriguez Marco, Ainara [10 ]
Levit, Noah A. [9 ]
机构：
[1] Univ Sheffield, Sheffield Dermatol Res, Sheffield, S Yorkshire, England
[2] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[3] Aarhus Univ Hosp, Aarhus, Denmark
[4] Univ British Columbia, Surrey, BC, Canada
[5] Prob Med Res, Waterloo, ON, Canada
[6] Univ Toronto, Toronto, ON, Canada
[7] CCA Med Res, Ajax, ON, Canada
[8] Vital Prospects Clin Res Inst, Tulsa, OK USA
[9] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[10] Sanofi Genzyme, Madrid, Spain
来源：
CLINICAL AND EXPERIMENTAL ALLERGY | 2022年 / 52卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P034
引用
收藏
页码：1014 / 1014
页数：1
相关论文
共 50 条
  • [1] Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial
    Beck, Lisa A.
    Deleuran, Mette
    Hong, H. Chih-Ho
    Adam, David N.
    Hussain, Iftikhar
    Zhang, Haixin
    Shabbir, Arsalan
    Rodriguez Marco, Ainara
    Levit, Noah A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB206 - AB206
  • [2] Long-term dupilumab efficacy is sustained in adults with moderate-to-severe atopic dermatitis transitioning from weekly to every other week dosing: results from an open-label extension trial
    Deleuran, M.
    Hong, H. C.
    Adam, D. N.
    Hussain, I.
    Zhang, H.
    Shabbir, A.
    Marco, A. R.
    Levit, N. A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E162 - E162
  • [3] LONG-TERM DUPILUMAB EFFICACY IS SUSTAINED IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMITITIS TRANSITIONING FROM WEEKLY TO EVERY OTHER WEEK DOSING: RESULTS FROM AN OPEN-LABEL EXTENSION TRIAL
    Beck, Lisa A.
    Deleuran, Mette
    Chih-Ho Hong, H.
    Adam, David N.
    Hussain, Iftikhar
    Zhang, Haixin
    Shabbir, Arsalan
    Rodriguez Marco, Ainara
    Levit, Noah A.
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 34
  • [4] Long-Term Efficacy Of Dupilumab In Adults With Moderate-to-Severe Atopic Dermatitis: Results From A 5-Year Open-Label Extension Trial
    Beck, Lisa
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Take-shi
    Galus, Ryszard
    Xiao, Jing
    Avetisova, Elena
    Du-bost-Brama, Ariane
    Shabbir, Arsalan
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB5 - AB5
  • [5] Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension trial up to 172 weeks
    Beck, L.
    Deleuran, M.
    Blauvelt, A.
    Thyssen, J.
    Bissonnette, R.
    de Bruin-Weller, M.
    Chen, Z.
    Levit, N.
    Rodriguez Marco, A.
    [J]. EXPERIMENTAL DERMATOLOGY, 2021, 30 : 11 - 12
  • [6] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [7] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
  • [8] 416 Long-term efficacy of dupilumab in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [9] Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial
    Blauvelt, A.
    Ladizinski, B.
    Prajapati, V. H.
    Laquer, V.
    Fischer, A.
    Eisman, S.
    Wu, T.
    Vigna, N.
    Teixeira, H. D.
    Liu, J.
    Eyerich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E142 - E142
  • [10] Safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: results from an open-label extension trial up to 5 years
    Beck, Lisa A.
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Takeshi
    Galus, Ryszard
    Khokhar, Faisal A.
    Coleman, Anna
    Gherardi, Guy
    Xiao, Jing
    Dingman, Robert
    Xu, Christine
    Avetisova, Elena
    Dubost-Brama, Ariane
    Shabbir, Arsalan
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12345